As women approach and pass through menopause, their bodies produce significantly less estrogen and progesterone, prompting scientists to investigate whether this hormonal drop contributes to higher dementia rates in women. Karyn Frick, a neuroscientist at the University of Wisconsin-Milwaukee, explains that neurons may become more susceptible to age-related decline and Alzheimer’s pathologies when these protective hormones disappear.
While the concept that hormone replacement therapy (HRT) could shield the brain is intuitive, clinical evidence has been inconsistent. Early data suggests that restoring estrogen during the window of early menopause might preserve cognitive health, but researchers emphasize that rigorous clinical trials are necessary to confirm these benefits.
Preliminary biological studies support the neuroprotective potential of estrogen. In animal models, the loss of estrogen leads to a reduction in dendritic spines, the structures responsible for receiving chemical signals between neurons. Furthermore, estrogen appears to influence how proteins are processed, promoting the cleavage of precursor proteins in a way that reduces the accumulation of amyloid beta, a key component of Alzheimer’s plaques. It may also inhibit the clumping of tau proteins, which form the neurofibrillary tangles characteristic of the disease.
Beyond direct cellular protection, estrogen may improve brain health indirectly by alleviating menopausal symptoms such as hot flashes and insomnia. Better sleep quality allows the brain to more effectively clear toxic proteins, whereas sleep deprivation has been linked to increased Alzheimer’s risk.
The history of HRT is complex. After gaining popularity in the 1990s, its use declined following the 2002 Women’s Health Initiative study, which highlighted various risks associated with both estrogen-only and combined therapies. Although some of those findings have been revisited, current guidelines recommend that women with a uterus take combined HRT to counteract estrogen’s thickening effect on the uterine lining, while estrogen-only therapy is reserved for those who have undergone a hysterectomy.
Recent observational data published in the journal Neurology indicates that estrogen-only HRT may be linked to a lower risk of dementia. The study, which analyzed over 21,000 women, found that those taking estrogen-only treatment showed fewer Alzheimer’s-related brain changes, better clinical outcomes, and superior memory test scores compared to untreated women. However, because the study did not track when participants started their therapy, it cannot establish causality.
These findings contrast with a 2023 observational study that reported an increased dementia risk among women taking estradiol, suggesting that the type of estrogen used may influence outcomes. This discrepancy highlights the need for further research to clarify the relationship between different estrogen formulations and brain health.
Timing appears to be a critical factor. Research led by the Alzheimer’s Drug Discovery Foundation indicates that initiating HRT after age 65 is associated with worse cognitive function and higher dementia risk. In contrast, starting therapy between ages 46 and 56 may offer protective benefits. A recent study in Alzheimer’s & Dementia found that early HRT use was particularly beneficial for women with surgical menopause, those carrying certain APOE gene variants, and women who experienced a shorter duration between puberty and menopause.
Despite these promising leads, Yuko Hara of the Alzheimer’s Drug Discovery Foundation notes that there is insufficient evidence to recommend HRT broadly for dementia prevention. The exception remains women who have had their ovaries surgically removed, as they experience an abrupt and early loss of estrogen. Currently, HRT is prescribed primarily to manage menopausal symptoms rather than to prevent cognitive decline.
Experts argue that definitive answers will require well-designed clinical trials that follow women from perimenopause through postmenopause, allowing for a more accurate assessment of how hormone therapy impacts long-term brain health.
Leave a Reply